Terkko Navigator / Wennerberg, K(rister)* (FIMM)

Comprehensive and unbiased multiparameter high-throughput screening by compaRe finds effective and subtle drug responses in AML models

Pancreatic Cancer Organoids in the Field of Precision Medicine: A Review of Literature and Experience on Drug Sensitivity Testing with Multiple Readouts and Synergy Scoring

Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia

Minimal information for chemosensitivity assays (MICHA): a next-generation pipeline to enable the FAIRification of drug screening experiments

Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments

Network-guided identification of cancer-selective combinatorial therapies in ovarian cancer

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia

CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis

Crowdsourced mapping of unexplored target space of kinase inhibitors

Selective drug combination vulnerabilities in STAT3- and TP53-mutant malignant NK cells

Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

Mitochondria in Their Prime Drive Venetoclax Response in Acute Myeloid Leukemia

Minimal information for Chemosensitivity assays (MICHA): A next-generation pipeline to enable the FAIRification of drug screening experiments

Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma

Immunogenomic Landscape of Hematological Malignancies

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia

Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition

Immunogenomic Landscape of Hematological Malignancies

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers

Prediction of drug combination effects with a minimal set of experiments

Identification of novel regulators of STAT3 activity

Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomics

Breeze: an integrated quality control and data analysis application for high-throughput drug screening

Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1

Exploration of databases and methods supporting drug repurposing: a comprehensive survey

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening

Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing

Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer

Atypical KRAS^G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival

ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors

Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify <em>Kras</em>-Mutant Lung Cancers

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma

Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets

8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia

Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas

Interactive visual analysis of drug-target interaction networks using Drug Target Profiler, with applications to precision medicine and drug repurposing

Anagrelide for Gastrointestinal Stromal Tumor

Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism

Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Corrigendum to "Searching for drug synergy in complex dose-response landscapes using an interaction potency model" [Comput. Struct. Biotechnol. J. 13 (2015) 504-513]